Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
<p>Design of dose-escalation phase. CRM, continuous reassessment model; Q3W, once every 3 weeks; 3Q4W, 3 weekly doses every 4 weeks</p>
Na minha lista:
Registos relacionados
-
Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
Por: Kristoffer Staal Rohrberg (15009138)
Publicado em: (2025) -
Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
Por: Kristoffer Staal Rohrberg (15009138)
Publicado em: (2025) -
Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
Por: Kristoffer Staal Rohrberg (15009138)
Publicado em: (2025) -
Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
Por: Kristoffer Staal Rohrberg (15009138)
Publicado em: (2025) -
Table 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
Por: Kristoffer Staal Rohrberg (15009138)
Publicado em: (2025)